Life360 unveils $7.99 QR tags for pets

Coherus Oncology reported interim phase 1b trial results showing tagmokitug, combined with Loqtorzi and chemotherapy, achieved a 75% overall response rate in esophageal cancer patients as a first-line therapy, regardless of PD-L1 status, according to the company.

Rio Tinto opened two lithium plants in Argentina, investing $1.4B to add 25,000 metric tons of lithium carbonate annually. The company aims to reach 200,000 tons by 2028, using DLE technology. Argentina's reforms and lithium reserves position it as a key player in the global market.

Coherus Oncology (CHRS) reported interim data for tagmokitug plus toripalimab and chemo in 1L ESCC, showing a confirmed ORR of 75% at cutoff, rising to 89% after two later PRs. The company plans to expand enrollment in 1L and 2L ESCC, with safety deemed acceptable. This data is early-to-mid stage validation for Coherus's CCR8 program.

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide SKNY-1’s Weight Reduction Without Significant Changes in Food Consumption Suggests a Pot

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase III trial, achieving 19.5-20.9% weight loss vs. Ozempic's 9.4%, and greater A1C reduction. Retatrutide also improved cardiovascular risk factors. Lilly and Novo are competitors in the obesity and type 2 diabetes market, with ongoing legal and market disputes.

Eli Lilly's experimental drug retatrutide showed greater improvement in type 2 diabetes measures than Novo's Ozempic in a Phase 3 trial, reducing A1C levels by 2.2 points vs. 1.8 for Ozempic. Retatrutide also led to more weight loss and better cardiovascular metrics but had higher side effects. Lilly plans to present detailed data later. Analysts see potential for premium pricing and $15B in 2032 sales if approved.